OT Cybersecurity for Pharmaceuticals
Protecting Pharmaceutical
Pharmaceutical manufacturers operate complex OT environments — from Distributed Control Systems (DCS) and SCADA to automated batch processing and cold chain management. These systems are directly responsible for product quality, process integrity, and ultimately patient safety.
Pharmaceutical Industry
With high-value intellectual property and life-critical products at stake, the pharmaceutical sector is a prime target for nation-state actors and organised cybercriminals. CyInfra helps pharmaceutical organisations protect their manufacturing OT without compromising GxP compliance or operational continuity.
Key Cybersecurity Challenges Facing the Pharmaceutical Sector
GxP and Regulatory Compliance
Meeting FDA 21 CFR Part 11, EU GMP Annex 11, and ISA/IEC 62443 requirements across interconnected manufacturing OT environments demands rigorous security controls and comprehensive audit capability.
Intellectual Property at Risk
Manufacturing formulas, R&D data, and process parameters stored in OT systems are high-value targets for state-sponsored espionage and organised criminal actors seeking competitive advantage.
Legacy Manufacturing Control Systems
DCS, SCADA, and batch control systems designed before modern cybersecurity requirements often cannot be patched, upgraded, or replaced without significant production and compliance impact.
Third-Party and Supply Chain Exposure
Raw material suppliers, contract manufacturers, and equipment vendors require access to manufacturing OT systems, creating third-party access pathways that significantly widen the attack surface.
The Threat Landscape in Pharmaceuticals
- Pharmaceutical OT environments are high-value targets for nation-state actors — particularly those seeking to steal drug formulations, clinical trial data, and manufacturing process intellectual property worth billions.
- ICS-specific malware including Industroyer, Triton, and Incontroller demonstrates that sophisticated attackers are developing capabilities specifically designed to compromise and manipulate industrial manufacturing control systems.
- Ransomware attacks on pharmaceutical manufacturers have caused extended production shutdowns, creating drug supply shortages with direct patient safety implications and severe regulatory and reputational consequences.
- Smart manufacturing and Industry 4.0 initiatives are increasing connectivity between enterprise networks and plant floor OT systems — expanding the attack surface faster than security programmes can keep pace.
CyInfra for Healthcare
Securing Your Pharmaceutical Operations
- Conduct OT risk assessments aligned with FDA cybersecurity guidance, EU GMP Annex 11, and ISA/IEC 62443 security level requirements across your manufacturing environment.
- Identify and protect crown jewel assets — DCS, SCADA, and batch control systems — from unauthorised access, manipulation, and data exfiltration.
- Implement network segmentation to isolate plant floor OT from enterprise IT, external vendor access, and supply chain connectivity.
- Establish GxP-compliant OT security policies covering change management, access control, audit trail integrity, and configuration management.
- Develop and test incident response plans to ensure rapid recovery from cyber events without compromising product quality, batch integrity, or regulatory standing.
Pharma OT systems must stay secure.
Protect critical hospital and pharmaceutical operations, ensure secure connected medical systems, and enable real-time monitoring of sensitive OT infrastructure.
Speak to our pharmaceutical OT security specialists
Protect patient safety and critical operations with OT cybersecurity, continuous monitoring, and regulation-aligned industrial defence systems.